Patient perspectives on the pathway to psoriatic arthritis diagnosis: results from a web-based survey of patients in the United States

Alexis Ogdie 1,2*, W. Benjamin Nowell 3, Eddie Applegate 3, Kelly Gavigan 3, Shilpa Venkatachalam 3, Marie de la Cruz 4, Emuella Flood 4, Ethan J. Schwartz 4, Beverly Romero 4 and Peter Hur 5

Abstract

Background: There are limited real-world data on the diagnostic experiences of patients with psoriatic arthritis (PsA), including medical care sought and potential barriers to diagnosis. We aim to describe patient experiences related to receiving a PsA diagnosis.

Methods: Ours was a mixed-method, 2-phase study. Phase 1 comprised concept elicitation and cognitive interviews with clinical experts and adults diagnosed with PsA to develop a cross sectional, web-based survey. US adults with a self-reported PsA diagnosis were recruited through a patient support community (CreakyJoints), an online patient research registry (ArthritisPower), and social media outreach. In Phase 2, the online survey collected data on sociodemographics, clinical symptoms, disease burden, and diagnosis history of survey respondents with PsA.

Results: Of the 203 respondents included, 172 (84.7%) were female, and the mean (SD) age was 51.6 (10.8) years. The time between seeking medical attention and receiving a diagnosis was < 6 months for 69 respondents, 6 months to 4 years for 68 respondents, and ≥ 5 years for 66 respondents. Most respondents sought care from general practitioners (79.8%) and rheumatologists (66.5%). Common initial symptoms that led respondents to seek medical attention were joint pain (70.0%) and stiffness (53.7%). Among the initial symptoms that led respondents to seek care, joint pain, swollen joints, and sausage-like fingers or toes (indicating dactylitis) were more common among respondents with shorter time to diagnosis, whereas stiffness, fatigue, enthesitis (indicated by foot problems, tendon and ligament pain), and back pain were more common among respondents with longer time to diagnosis. Common misdiagnoses were psychosomatic issues (26.6%) and osteoarthritis (21.7%). Respondents with shorter times to diagnosis had lower frequencies of misdiagnosis.

Conclusions: Respondents with PsA reported delays in diagnosis and misdiagnoses on their journey to a PsA diagnosis. Symptom differences, such as enthesitis and stiffness, were noted among respondents with shorter vs longer time to diagnosis. Increased understanding of diagnostic barriers may lead to earlier diagnosis and appropriate management to improve outcomes.

Keywords: Psoriatic arthritis, Spondyloarthritis, Diagnosis, Surveys and questionnaires

© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Psoriatic arthritis (PsA) is a chronic inflammatory disease of the skin and musculoskeletal system with an estimated incidence of 6 per 100,000 and a prevalence of approximately 1 to 2 per 1000 in the general population [1–3]. PsA is typically characterized by axial skeleton disorders, nail and skin changes, peripheral joint inflammation, enthesitis, and dactylitis, either alone or in combination [4]. This disease is also associated with numerous comorbidities, including hypertension and other cardiovascular conditions, autoimmune diseases, type 2 diabetes mellitus, depression, and chronic obstructive pulmonary disease [5]. Often these comorbidities contribute to the impairment of quality of life, psychological and physical function, and increase in overall clinical burden [6]. Despite advances in treatment, unmet needs still exist in the diagnosis and treatment of PsA [7]. According to the Classification Criteria for Psoriatic Arthritis, a patient must have ≥3 established inflammatory articular diseases of the following: current psoriasis (2 points), personal or family history of psoriasis; current dactylitis or prior history as recorded by a rheumatologist; juxta-articular new bone formation; negative expression of rheumatoid factor; and nail psoriasis, including onycholysis, pitting, and hyperkeratosis [8, 9].

Early diagnosis of PsA is important because a delayed diagnosis significantly contributes to negative patient outcomes [10, 11]. Patients with untreated PsA, even with a 6-month delay from symptom onset to the first rheumatology visit [12], may develop peripheral joint erosions, progressive joint damage, and severe physical limitations [13]. Most patients initially seek medical care from general practitioners [14]; however, patients in consultation with a general practitioner may not receive a timely diagnosis of PsA because it may be challenging for nonrheumatologists to distinguish PsA from other forms of arthritis [15]. Estimates indicate that 6 to 42% of patients with psoriasis eventually develop PsA [16, 17].

There is limited information on the real-world, diagnostic experiences of patients with PsA, including medical care sought and potential barriers to diagnosis. The objective of this study was to determine patient experiences related to the diagnosis of PsA among patients with PsA in the United States.

Methods
Data source and study variables
This was a mixed-method, 2-phase study adhering to the Checklist for Reporting Results of Internet E-Surveys (CHERRIES) [18]. Phase 1 consisted of targeted literature review and qualitative interviews with clinical experts and adults diagnosed with PsA via telephone to identify key concepts associated with disease burden and treatment experience (Additional file 1: Table S1 and Additional file 2: Table S2). Verbal informed consent was obtained from all telephone interviewees prior to their participation. The key concepts identified were used to develop an online survey fielded to adults with PsA in Phase 2 (Additional file 3: Table S3). Electronic consent was obtained prior to survey participation. The final questionnaire (Additional file 4: Appendix) consisted of randomized or alternated items to prevent bias, and adaptive questioning was used to reduce the number and complexity of the questions. The questionnaire was composed of 42 questions, with approximately 4–5 questions per page distributed over 10 pages. Only completed responses were analyzed; all questions were enforced, and “not applicable” or “other” responses were provided for certain questions. Respondents were able to review and change their answer through a Back button. By collecting cookies, the Qualtrics platform prevented participants from retaking the survey if they have already completed it. If the participant started the survey, stopped and closed their browser, and then clicked on the email link again sometime later, the participant would be directed back to the page they had left off on, rather than starting the survey over again. As a result, the participants analyzed were unique site visitors. IP address of the client computer was not used to prevent duplicate entries from the same user. An incentive of $25 was provided to participants who completed the entire survey. Only completed questionnaires were analyzed. Participants were required to fill out all questions displayed to them, as the skip logic would not function properly otherwise. The incomplete responses (questionnaires which terminated early) were not analyzed. The average length of time participants spent completing the survey was 27 min. Questionnaires were excluded that were less than 8 min, which was determined by testing the survey and answering questions in a way that would produce the least number of subsequent questions, based on skip logic. The participants were given a unique ID that was passed from the recruitment email to the survey. This ID was used to remove duplicate survey entries. While this was not a “closed” survey, users were prevented from restarting the questionnaire once they had completed it and were directed to the page they had left off if they had paused in the middle of taking it and then resumed. On the chance that a participant completed the survey more than once (for example, by using a different computer), then the unique ID assigned to the user that is passed to the survey from the recruitment email was used to monitor duplicate responses. If a duplicate response was found, the first entry was kept and the most recent was removed from analysis.

Survey participants in the United States aged ≥18 years with a self-reported diagnosis of PsA were recruited for our study via CreakyJoints (https://creakyjoints.org),
ArthritisPower (https://arthritispower.creakyjoints.org), and social media outreach in a process similar to a previously reported survey of patients with ankylosing spondylitis [19]. The Global Healthy Living Foundation (GHLF) is the umbrella organization of both CreakyJoints and ArthritisPower, and GHLF investigators identified eligible members based on profile information, which was voluntarily provided, including age, sex, location via zip code, condition, and current medical prescription; no personal information was stored. Our study has been reviewed and approved by a central institutional review board (IRB; Salus IRB). All research was conducted in compliance with the Declaration of Helsinki of 1964 and all later amendments.

This survey workflow went from the recruitment email to the first page of the survey (informed consent form). Of a total of 326 visitors to the survey site, 258 unique visitors agreed to participate and initiated the survey, resulting in a participation rate of 79.1%. A total of 203 respondents completed the questionnaire for a completion rate of 78.7%. Emails were first sent on September 5, 2017, and the final response was received on October 13, 2017, totaling 38 days of data collection.

**Study variables**

Using our web-based survey, respondents provided sociodemographic characteristics (age, sex, race, education, employment, marital status, yearly income, and type of health insurance), clinical information (Routine Assessment of Patient Index Data 3 [RAPID3] cumulative score [1–30], [20–22], RAPID3 categorical disease activity/severity [near remission = 1–3, low = 4–6, medium = 7–12, high = 13–30], extent of psoriasis captured using the Patient Report of Extent of Psoriasis Involvement [23], current symptoms, and other comorbidities), and diagnosis history (time since onset of symptoms, first PsA symptom experienced that prompted the respondent to seek medical help, time between symptom onset and seeking treatment, the types of healthcare providers consulted, time between seeking medical treatment and receipt of formal diagnosis, time since official PsA diagnosis received, and misdiagnoses obtained). Stratification of data was performed based on time between seeking medical attention and receipt of formal diagnosis of PsA; time cutoffs of < 6 months, 6 months to 4 years, and ≥ 5 years were chosen post hoc to yield an even distribution of the number of respondents across groups.

**Data analysis**

Survey results were reported descriptively. Continuous variables were presented using means and SDs, and categorical variables were presented using frequencies and percentages. \( \chi^2 \) tests were used to analyze differences across the groups that were stratified post hoc by time to PsA diagnosis; \( P < 0.05 \) was considered statistically significant and each test between the 3 groups was a unique hypothesis.

**Results**

**Sociodemographic and clinical characteristics of respondents with PsA**

Among the 203 respondents included in the study, the mean (SD) age was 51.6 (10.8) years; 188 (92.6%) were white, and 172 (84.7%) were female (Table 1). Approximately one-third of respondents reported full-time employment (\( n = 73 \) [36.0%]), and another one-third were disabled and not working (\( n = 71 \) [35.0%]). Overall, the time between seeking medical attention and receiving a diagnosis was < 6 months for 69 respondents, 6 months to 4 years for 68 respondents, and ≥ 5 years for 66 respondents. Respondents with faster times to diagnosis (< 6 months) appeared to be slightly older, have undergraduate/postgraduate education, were less likely to be disabled and not working, and were more likely to earn ≥ $100,000/year compared with respondents with longer times to diagnosis.

More than two-thirds of respondents (68.5%) reported high disease severity as assessed by RAPID3 score (Table 2). Approximately one-fifth of respondents (\( n = 41 \) [20.2%]) reported moderate to severe extent of psoriasis, assessed by the amount of palm surface area affected. With regard to current symptoms, respondents most often experienced joint pain (86.7%), fatigue (83.3%), and stiffness (78.3%).

**Medical care, diagnosis delay, and misdiagnoses reported by respondents with PsA**

The mean (SD) time from symptom onset was 15.1 (11.8) years, and the mean (SD) time since receipt of an official PsA diagnosis was 8.7 (9.6) years. When stratified by time between seeking medical attention and receipt of formal diagnosis (< 6 months, 6 months to 4 years, and ≥ 5 years), the mean (SD) years since first symptom experienced were 13.4 (13.2), 10.7 (7.6), and 21.3 (11.5) years, respectively (\( P < 0.001 \)). With regard to prescription medication, > 80% of respondents had received biologics, conventional synthetic disease-modifying antirheumatic drugs, and/or nonsteroidal anti-inflammatory drugs. The most common symptoms that led to seeking medical care were joint pain (70.0%), stiffness (53.7%), and swollen joints (49.8%) (Fig. 1). Joint pain, swollen joints, reduced range of motion in the joints of arms and legs, and sausage-like fingers or toes (indicating dactylitis) were more prevalent among respondents with shorter time to diagnosis, whereas stiffness, fatigue, foot problems, tendon...
and ligament pain (indicating enthesitis), and back pain were more common among respondents with longer time to diagnosis. Nearly two-thirds of respondents (65.1%) sought medical treatment within 1 year of symptom onset; 10.3% sought treatment after 1–2 years, and 24.6% sought treatment > 2 years after symptom onset. During their diagnosis journey, respondents reported that they most commonly sought care from a general practitioner

### Table 1: Sociodemographic characteristics of respondents with PsA, stratified by time between seeking medical attention and receiving formal diagnosis

| Characteristics | Total Respondents (N = 203) | < 6 Months (n = 69) | 6 Months to 4 Years (n = 68) | ≥ 5 Years (n = 66) | P Value |
|-----------------|-------------------------------|---------------------|-----------------------------|-------------------|---------|
| Age, years      |                               |                     |                             |                   |         |
| Mean (SD)       | 51.6 (10.8)                   | 53.3 (13.0)         | 50.6 (9.4)                  | 51.0 (9.6)        | 0.298   |
| Median (IQR)    | 51.0 (15.0)                   | 53.0 (16.0)         | 49.0 (13.5)                 | 50.0 (16.0)       |         |
| Range           | 21.0–82.0                     | 21.0–82.0           | 31.0–76.0                   | 29.0–78.0         |         |
| Female, n (%)   | 172 (84.7)                    | 56 (81.2)           | 58 (85.3)                   | 58 (87.9)         |         |
| Race, n (%)     |                               |                     |                             |                   | 0.052   |
| White           | 188 (92.6)                    | 59 (85.5)           | 67 (98.5)                   | 62 (93.9)         |         |
| Black/African American | 2 (1.0)                  | 0                   | 2 (3.0)                     |                   |         |
| American Indian/Alaska Native | 2 (1.0)                  | 2 (2.9)             | 0                            | 0                 |         |
| Asian           | 2 (1.0)                       | 2 (2.9)             | 0                            | 0                 |         |
| Multiracial     | 7 (3.4)                       | 4 (5.8)             | 1 (1.5)                     | 2 (3.0)           |         |
| Prefer not to answer | 2 (1.0)                           | 2 (2.9)             | 0                            | 0                 |         |
| Highest level of education, n (%) | 10 (4.9)                    | 3 (4.3)             | 1 (1.5)                     | 6 (9.1)           | 0.648   |
| High school/GED | 10 (4.9)                     | 3 (4.3)             | 1 (1.5)                     |                   |         |
| Some college (no degree) | 47 (23.2)                    | 15 (21.7)           | 17 (25.0)                   | 15 (22.7)         |         |
| Associate’s degree/trade school/certificate program | 43 (21.2) | 14 (20.3) | 15 (22.1) | 14 (21.2) |         |
| Undergraduate/postgraduate degree | 103 (50.7) | 37 (53.6) | 35 (51.5) | 31 (47.0) |         |
| Current employment status, n (%)<sup>a</sup> | 73 (36.0) | 23 (33.3) | 24 (35.3) | 26 (39.4) | 0.769   |
| Employed full time | 73 (36.0) | 23 (33.3) | 24 (35.3) | 26 (39.4) | 0.769   |
| Employed part time<sup>b</sup> | 10 (4.9) | 6 (8.7) | 4 (5.9) | 0 | 0.042   |
| Disabled/not working | 71 (35.0) | 21 (30.4) | 24 (35.3) | 26 (39.4) | 0.546   |
| Retired | 28 (13.8) | 13 (18.8) | 8 (11.8) | 7 (10.6) | 0.363   |
| Other | 33 (16.3) | 11 (15.9) | 13 (19.1) | 9 (13.6) | 0.704   |
| Relationship status, n (%) | 137 (67.5) | 42 (60.9) | 48 (70.6) | 47 (71.2) | 0.349   |
| Married/partnered | 137 (67.5) | 42 (60.9) | 48 (70.6) | 47 (71.2) | 0.349   |
| Single/separated/divorced | 56 (27.6) | 21 (30.4) | 17 (25.0) | 18 (27.3) |         |
| Widowed | 10 (4.9) | 6 (8.7) | 3 (4.4) | 1 (1.5) |         |
| Annual income, n (%) | 73 (36.0) | 25 (36.2) | 25 (36.8) | 23 (34.8) | 0.117   |
| < $50,000 | 73 (36.0) | 25 (36.2) | 25 (36.8) | 23 (34.8) | 0.117   |
| $50,000 to $99,999 | 74 (36.5) | 18 (26.1) | 29 (42.6) | 27 (40.9) | 0.117   |
| ≥ $100,000 | 41 (20.2) | 21 (30.4) | 11 (16.2) | 9 (13.6) | 0.117   |
| Prefer not to answer | 15 (7.4) | 5 (7.2) | 3 (4.4) | 7 (10.6) |         |
| Health insurance, n (%)<sup>a</sup> | 132 (65.0) | 43 (62.3) | 45 (66.2) | 44 (66.7) | 0.868   |
| Private insurance | 132 (65.0) | 43 (62.3) | 45 (66.2) | 44 (66.7) | 0.868   |
| Medicare/Medicaid | 74 (36.5) | 28 (40.6) | 25 (36.8) | 21 (31.8) | 0.562   |
| Other government insurance | 10 (4.9) | 4 (5.8) | 3 (4.4) | 3 (4.5) | 1.000   |
| Other/don’t know | 4 (2.0) | 2 (2.9) | 1 (1.5) | 1 (1.5) | 1.000   |

<sup>a</sup> Respondents could have selected > 1 option

<sup>b</sup> P < 0.05 comparing respondents with time to PsA diagnosis of < 6 months, 6 months to 4 years, and ≥ 5 years

GED, general equivalency diploma; PsA, psoriatic arthritis.
Table 2: Clinical characteristics of respondents with PsA, stratified by time between seeking medical attention and receiving formal diagnosis

| Characteristics                                                                 | Total Respondents (N = 203) | < 6 Months (n = 69) | 6 Months to 4 Years (n = 68) | ≥ 5 Years (n = 66) | P Value |
|---------------------------------------------------------------------------------|-----------------------------|---------------------|-----------------------------|-------------------|---------|
| **RAPID3 cumulative score (0–30)**                                              |                             |                     |                             |                   |         |
| Mean (SD)                                                                       | 14.7 (5.8)                  | 14.3 (6.5)          | 14.5 (5.8)                  | 15.4 (5.0)        | 0.559   |
| Median (IQR)                                                                    | 15.5 (8.5)                  | 14.5 (10.2)         | 15.5 (8.9)                  | 16.3 (6.0)        |         |
| Range                                                                           | 1.3–29.0                    | 1.3–29.0            | 2.0–24.3                    | 2.0–25.2          |         |
| **RAPID3 disease severity category, n (%)**                                      |                             |                     |                             |                   | 0.688   |
| Near remission (1–3)                                                            | 5 (2.5)                     | 2 (2.9)             | 2 (2.9)                     | 1 (1.5)           |         |
| Low (4–6)                                                                       | 14 (6.9)                    | 6 (8.7)             | 5 (7.4)                     | 3 (4.5)           |         |
| Medium (7–12)                                                                   | 45 (22.2)                   | 18 (26.1)           | 16 (23.5)                   | 11 (16.7)         |         |
| High (13–30)                                                                    | 139 (68.5)                  | 43 (62.3)           | 45 (66.2)                   | 51 (77.3)         |         |
| **Years since first symptom experienced**                                       |                             |                     |                             |                   | < 0.001 |
| Mean (SD)                                                                       | 15.1 (11.8)                 | 13.4 (13.2)         | 10.7 (7.6)                  | 21.3 (11.5)       |         |
| Median (IQR)                                                                    | 12.0 (13.0)                 | 8.0 (13.0)          | 9.0 (10.0)                  | 18.0 (18.0)       |         |
| Range                                                                           | 0–60.0                      | 0–60.0              | 0–39.0                      | 3.0–52.0          |         |
| **Years since official diagnosis**                                              |                             |                     |                             |                   | 0.073   |
| Mean (SD)                                                                       | 8.7 (9.6)                   | 10.8 (12.4)         | 8.1 (7.3)                   | 7.3 (7.9)         |         |
| Median (IQR)                                                                    | 6.0 (10.0)                  | 7.0 (11.0)          | 6.5 (9.0)                   | 5.0 (8.0)         |         |
| Range                                                                           | 0–60.0                      | 0–60.0              | 0–39.0                      | 0–42.0            |         |
| **Extent of psoriasis (assessed by area covered in number of palms), n (%)**    |                             |                     |                             |                   | 0.259   |
| Little to no psoriasis (< 1 palm)                                              | 105 (51.7)                  | 33 (47.8)           | 43 (63.2)                   | 29 (43.9)         |         |
| Only a few patches (1–2 palms)                                                  | 45 (22.2)                   | 14 (20.3)           | 12 (17.6)                   | 19 (28.8)         |         |
| Scattered patches (3–10 palms)                                                  | 41 (20.2)                   | 17 (24.6)           | 9 (13.2)                    | 15 (22.7)         |         |
| Extensive psoriasis (> 10 palms)                                                | 12 (5.9)                    | 5 (7.2)             | 4 (5.9)                     | 3 (4.5)           |         |
| **Current symptoms (in ≥ 50% of respondents), n (%)**                          |                             |                     |                             |                   |         |
| Joint pain                                                                       | 176 (86.7)                  | 57 (82.6)           | 61 (89.7)                   | 58 (87.9)         | 0.498   |
| Fatigue                                                                         | 169 (83.3)                  | 56 (81.2)           | 57 (83.8)                   | 56 (84.8)         | 0.867   |
| Stiffness                                                                        | 159 (78.3)                  | 53 (76.8)           | 51 (75.0)                   | 55 (83.3)         | 0.456   |
| Swollen joints                                                                   | 127 (62.6)                  | 42 (60.9)           | 45 (66.2)                   | 40 (60.6)         | 0.759   |
| Reduced range of motion in the joints of the arms and legs                      | 122 (60.1)                  | 43 (62.3)           | 38 (55.9)                   | 41 (62.1)         | 0.679   |
| Back pain                                                                       | 119 (58.6)                  | 39 (56.5)           | 37 (54.4)                   | 43 (65.2)         | 0.414   |
| Foot problems                                                                    | 115 (56.7)                  | 34 (49.3)           | 37 (54.4)                   | 44 (66.7)         | 0.115   |
| Tendon or ligament pain a                                                       | 109 (53.7)                  | 27 (39.1)           | 37 (54.4)                   | 45 (68.2)         | 0.003   |
| Difficulty walking                                                               | 108 (53.2)                  | 39 (56.5)           | 33 (48.5)                   | 36 (54.5)         | 0.615   |
| Reduced range of motion in spine and/or hips                                    | 107 (52.7)                  | 34 (49.3)           | 34 (50.0)                   | 39 (59.1)         | 0.459   |
| **Other health conditions (in ≥ 25% of respondents), n (%)**                    |                             |                     |                             |                   |         |
| Depression                                                                       | 126 (62.1)                  | 35 (55.1)           | 49 (72.1)                   | 39 (59.1)         | 0.105   |
| Anxiety                                                                         | 118 (58.1)                  | 38 (55.1)           | 40 (58.8)                   | 40 (60.6)         | 0.806   |
| Hypertension                                                                    | 97 (47.8)                   | 39 (56.5)           | 28 (41.2)                   | 30 (45.5)         | 0.178   |
| Migraines                                                                       | 90 (44.3)                   | 24 (34.8)           | 34 (50.0)                   | 32 (48.5)         | 0.142   |
| Fibromyalgia a                                                                  | 77 (37.9)                   | 18 (26.1)           | 30 (44.1)                   | 29 (43.9)         | 0.043   |
| Irritable bowel syndrome a                                                      | 76 (37.4)                   | 16 (23.2)           | 26 (38.2)                   | 34 (51.5)         | 0.003   |
| Seasonal allergies                                                              | 70 (34.5)                   | 24 (34.8)           | 20 (29.4)                   | 26 (39.4)         | 0.464   |
| Dyslipidemia                                                                    | 64 (31.5)                   | 22 (31.9)           | 19 (27.9)                   | 23 (34.8)         | 0.689   |
Table 2 Clinical characteristics of respondents with PsA, stratified by time between seeking medical attention and receiving formal diagnosis (Continued)

| Characteristics                              | Total Respondents (N = 203) | < 6 Months (n = 69) | 6 Months to 4 Years (n = 68) | ≥ 5 Years (n = 66) | P Value |
|----------------------------------------------|-----------------------------|---------------------|-----------------------------|-------------------|---------|
| Gastroesophageal reflux disease              |                             |                     |                             |                   |         |
| Sleep apnea                                  |                             |                     |                             |                   |         |
| Prescription medication ever taken, n (%)    |                             |                     |                             |                   |         |
| Biologic                                     | 176 (86.7)                  | –                   | –                           | –                 | –       |
| Nonbiologic DMARD                            | 174 (85.7)                  | –                   | –                           | –                 | –       |
| Antidepressant                                | 109 (53.7)                  | –                   | –                           | –                 | –       |
| Steroid medication                           | 162 (79.8)                  | –                   | –                           | –                 | –       |
| NSAID                                        | 167 (82.3)                  | –                   | –                           | –                 | –       |
| Opioid pain medication                       | 96 (47.3)                   | –                   | –                           | –                 | –       |
| Other pain medication                        | 132 (65.0)                  | –                   | –                           | –                 | –       |
| Sleep medication                             | 67 (33.0)                   | –                   | –                           | –                 | –       |
| Other                                         | 58 (28.6)                   | –                   | –                           | –                 | –       |
| None                                         | 3 (1.5)                     | –                   | –                           | –                 | –       |

* P < 0.05 comparing respondents with time to PsA diagnosis of < 6 months, 6 months to 4 years, and ≥ 5 years

Fig. 1 Common first symptoms to prompt seeking health care among respondents with PsA, stratified by time between seeking medical attention and receiving formal diagnosis. * PsA: psoriatic arthritis. * Respondents could have selected > 1 option

DMARD disease-modifying antirheumatic drug, NSAID nonsteroidal anti-inflammatory drug, PsA psoriatic arthritis, RAPID3 Routine Assessment of Patient Index Data 3
(79.8%), rheumatologist (66.5%), dermatologist (33.0%), and/or orthopedist (21.7%) (Fig. 2). Respondents with increasing times to diagnosis (< 6 months, 6 months to 4 years, and ≥ 5 years) were more likely to seek medical consultation from general practitioners/family doctors ($P = 0.043$), orthopedists ($P < 0.001$), chiropractors ($P = 0.033$), urgent care/emergency department doctors ($P = 0.289$), and sports medicine specialists ($P = 0.005$), whereas respondents with shorter times to diagnosis tended to seek care from dermatologists ($P = 0.386$) and rheumatologists ($P = 0.209$). The most common misdiagnoses prior to PsA were psychosomatic disorder (26.6%), osteoarthritis (21.7%), anxiety/depression (18.2%), and orthopedic problems (18.2%) (Fig. 3). Only 8 respondents (3.9%) reported that they had never received a misdiagnosis. All misdiagnoses were more prevalent with increasing time to diagnosis.

**Discussion**

In this study, we examined the self-reported experiences of US respondents with PsA related to obtaining a diagnosis of PsA. Overall, approximately only one-third of respondents sought medical treatment within 1 year since the onset of symptoms, most of which were musculoskeletal manifestations (e.g., joint pain and swelling). Respondents also consulted a variety of healthcare providers, and misdiagnosis prior to receiving the PsA diagnosis was common.

Differences in disease symptoms were observed among respondents with shorter vs longer time to PsA diagnosis. Respondents with shorter time to diagnosis had more occurrences of joint pain, swollen joints, reduced range of motion in the joints of arms and legs, and sausage-like fingers or toes (indicating dactylitis), whereas respondents with longer time to diagnosis had more occurrences of foot problems, neck pain, difficulty walking, uveitis, tendon or ligament pain (indicating enthesitis), and fatigue. These findings suggest that more noticeable symptoms, such as dactylitis and typical joint symptoms, may be more obvious indicators of PsA, leading to a shorter time to diagnosis, whereas less recognized PsA symptoms such as enthesitis, fatigue, and back pain are not as likely to signal a physician to think about PsA. Because a delay in PsA diagnosis contributes to poor outcomes [12], the early recognition of heterogenous PsA symptoms is important for favorable consequences. Patients with delays in diagnosis of PsA have been reported to present with a greater rate of clinical progression and worse physical function compared with patients with an undelayed diagnosis [24–26], and observational studies reported improved outcomes among patients with PsA who were treated soon after receiving a diagnosis of PsA [12, 24, 26]. Improved outcomes after early detection and treatment may be long lasting [25].

Because PsA is often more challenging to diagnose than rheumatoid arthritis [27], a lack of awareness among
general practitioners, dermatologists, and primary care physicians can delay the referral of a patient to rheumatologists [28]. Our study revealed that respondents with PsA consulted with several types of healthcare providers during the diagnosis process. In our study, almost 80% of respondents sought medical help from general practitioners and two-thirds from rheumatologists. Another analysis involving 5604 patients with psoriasis or PsA from the National Psoriasis Foundation survey panels reported that of patients who were seeing physicians, 78% consulted with specialists (either a dermatologist or a rheumatologist) and 22% saw internal medicine physicians, family practitioners, or other medical providers [14]. In our study, respondents with increased times to diagnosis were more likely to see general practitioners/family doctors, orthopedists, chiropractors, urgent care/emergency department doctors, and sports medicine specialists, suggesting that they were seeing multiple types of physicians before receiving an accurate PsA diagnosis. Respondents with shorter times to diagnosis were more likely to consult with dermatologists and rheumatologists. Because an estimated 80 to 84% of patients with PsA have psoriasis that precedes arthritis [17, 29], dermatologists are poised for early detection of PsA and rapid referrals to rheumatology. Recommendations for the identification and subsequent referral of patients with inflammatory arthritis have been suggested, including community case searches, public awareness programs, patient education sites on the internet, education programs, self-administered surveys, and referral guidelines for primary care providers [7, 30]. Implementation of such proposals has been shown to positively impact prompt diagnosis [31]. Additionally, validated screening tools to aid in the earlier detection of PsA are also available; some will capture PsA features such as back pain and enthesitis. Examples of PsA screening tools include the Psoriasis Epidemiology Screening Tool [15], Toronto Psoriatic Arthritis Screening (ToPAS) [32], and ToPAS 2 [33]. Results of screening questionnaires administered by healthcare providers in nonrheumatology settings may allow for timely rheumatologist referral and lead to an earlier diagnosis of PsA. Integrated, multidisciplinary clinics involving dermatologists and rheumatologists may substantially increase PsA referral and detection [34]; such settings are available in the United States and in Europe—in Munich, an increase in PsA diagnoses was observed among patients with psoriasis under the primary care of dermatologists when given access to the rheumatology unit [7].

There are limitations to our study, and the findings from this study should be interpreted in the context of limitations inherent to all patient surveys. Respondent perspectives may be subject to recall bias regarding their diagnosis experience. Survey respondents were interfacing within an online community and may have been more likely to participate regularly in research studies.
and may be more interested in managing their disease. The study relied on self-report of physician diagnosis of PsA; clinician-reported confirmation of diagnosis was not obtained.

**Conclusions**

Our study showed that many people living with PsA faced a winding path to arrive at a diagnosis, migrating through various types of healthcare providers prior to the diagnosis. Respondents with shorter times to diagnosis tended to seek care from dermatologists and rheumatologists. Many respondents encountered substantial delays and misdiagnoses before finally receiving a PsA diagnosis. Differences in presenting symptoms may have played a role in time to diagnosis. Symptom differences such as enthesitis and stiffness were observed among respondents with shorter vs longer time to diagnosis. Increased recognition of heterogeneous symptoms associated with PsA, as well as understanding existing diagnostic barriers, may lead to prompt diagnosis and initiation of appropriate treatment that may improve outcomes.

**Supplementary information**

**Supplementary information** accompanies this paper at https://doi.org/10.1186/s41927-019-0102-7.

**Additional file 1: Table S1.** Summary of the targeted literature review conducted for the identification of key concepts associated with disease burden and treatment experience.

**Additional file 2: Table S2.** Summary table of interview responses with clinical experts and adults with PsA.

**Additional file 3: Table S3.** Concept elicitation from interviews with clinical experts and adults with PsA.

**Additional file 4.** Supplemental Appendix -- Survey.

**Abbreviations**

GHLF; Global Healthy Living Foundation; PsA; Psoriatic arthritis; RAPID3; Routine Assessment of Patient Index Data 3; SD: Standard deviation; ToPAS; Toronto Psoriatic Arthritis Screening; US: United States

**Acknowledgements**

Support for third-party writing assistance for this manuscript, furnished by Eric Deutsch, PhD, CNMP, and Khng Bekdache, PhD, of Health Interactions, Inc., was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. A portion of these data was presented as a poster presentation at the 2018 Annual European Congress of Rheumatology meeting [35].

**Authors’ contributions**

Study design – AO, WBN, EA, KG, SV, MDLC, EF, EJS, BR. Data acquisition/analysis – WBN, EA, SV, EF, EJS, BR, PH. Data interpretation – AO, WBN, KG, SV, MDLC, EF, EJS, BR, PH. Manuscript preparation – AO, WBN, KG, SV, MDLC, EF, EJS, BR, PH. All authors have read and approved the final manuscript.

**Funding**

The design and conduct of the study were a collaborative effort between GHLF and Novartis Pharmaceuticals Corporation, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript.

**Availability of data and materials**

The datasets generated and/or analyzed in this study are not publicly available, but are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Our study has been reviewed and approved by a central institutional review board (IRB; Salus IRB). All research was conducted in compliance with the Declaration of Helsinki of 1964 and all later amendments. All participants were required to provide verbal and electronic consent prior to participating.

**Consent for publication**

Not applicable.

**Competing interests**

A. Ogdie has received consulting fees from AbbVie, Amgen, BMS, Celgene, Lilly, Novartis, Pfizer, and Takeda, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, Pfizer, and Novartis. W. B. Nowell; K. Gavigan; and S. Venkataraman are employees of Global Healthy Living Foundation. E. Applegate is a patient advocate affiliated with Global Healthy Living Foundation. M. de la Cruz, B. Romero, and E. Schwartz are employees of ICON, which was contracted by Novartis to conduct the study. E. Flood was an employee of ICON at the time of the analysis. P. Hur is an employee of Novartis Pharmaceuticals Corporation.

**Author details**

1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 2Hospital of the University of Pennsylvania, 3400 Spruce Street, 5 White Building, Philadelphia, PA 19104-4283, USA. 3Global Healthy Living Foundation, Upper Nyack, NY, USA. 4ICON, Gaithersburg, MD, USA. 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

**Received:** 28 May 2019 **Accepted:** 30 October 2019

**Published online:** 1 January 2020

**References**

1. Madlind TM, Apalset EM, Johannessen AE, Rossebø B, Brun JG. Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway. J Rheumatol. 2005;32(10):1918–22.
2. Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. Drugs. 2002;62(17):2447–57.
3. Gladman DD. Current concepts in psoriatic arthritis. Curr Opin Rheumatol. 2002;14(4):361–6.
4. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–70.
5. Ogdie A, Schwartzzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2011;23(2):118–26.
6. Wei JC, Baeten D, Sieper J, Deodhar A, Rhoesker V, Martin R, et al. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies. Int J Rheum Dis. 2017;20(5):589–96.
7. Hellwell P, Coates L, Chandran V, Gladman D, de Wit M, Fitzgerald O, et al. Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res. 2014;66(12):1759–66.
8. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):S81–64.
9. Taylor W, Gladman D, Hellwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73.
10. McHugh NJ. Early psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):615–22.
11. Raychaudhuri SP, Wilken R, Sukhov AC, Raychaudhuri SK, Mavreakis E. Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun. 2017;62:21–37.
12. Haroon M, Gallagher P, Fitzgerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045–50.
13. Gottlieb AB, Mease PJ, Mark Jackson J, Eisen D, Amy Xia H, Asare C, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices. J Dermatolog Treat. 2006;17(5):279–87.
14. Bhutani T, Wong JW, Bebo BF, Armstrong AW. Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. JAMA Dermatol. 2013;149(6):717–21.
15. Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (Pest) questionnaire. Clin Exp Rheumatol. 2009;27(3):469–74.

16. Doshi JA, Takeshita J, Pinto L, Li P, Yu X, Rao P, et al. Bolic therapy adherence, discontinuation, switching, and restarting among patients with psoriatic arthritis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057–65.

17. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):545–68.

18. Eysenbach G. Improving the quality of web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res. 2004;6(3):e34.

19. Ogdie A, Benjamin Nowell W, Reynolds R, Gavigan K, Venkatachalam S, de la Cruz M, et al. Real-world patient experience on the path to diagnosis of ankylosing spondylitis. Rheumatol Ther. 2019;6(2):255–67.

20. Coates LC, Tillett W, Shaddick G, Pincus T, Kavanaugh A, Helliwell PS. Value of the Routine Assessment of Patient Index Data 3 in patients with psoriatic arthritis: results from a tight-control clinical trial and an observational cohort. Arthritis Care Res. 2018;70(8):1198–205.

21. Pincus T. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care? Bull NYU Hosp Jt Dis. 2009;67(3):254–65.

22. Pincus T, Yazici Y, Castrejon I. Pragmatic and scientific advantages of MDHAQ/ RAPID3 completion by all patients at all visits in routine clinical care. Bull NYU Hosp Jt Dis. 2012;70(Suppl 1):30–6.

23. Domnach ED, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Reliability, validity and responsiveness to change of the Disease Activity Measure for Ankylosing Spondylitis. J Rheumatol. 2001;28(1):260–3.

24. Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis, who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70(12):2152–4.

25. Theander E, Husmark T, Alenius GM, Larsson PT, Telemen A, Geijer M, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73(2):407–13.

26. Tillett W, Jadon D, Shaddick G, Cavill C, Kordonskyh E, de Vries CS, et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis. 2013;72(8):1358–61.

27. Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3–17.

28. Betteridge N, Boehncke WH, Bundy C, Gossec L, Gatacapis J, Augustin M. Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience. J Eur Acad Dermatol Venereol. 2016;30(4):575–83.

29. Villani AP, Rouzaud M, Sevain M, Barnette T, Paul C, Richard MA, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;72(2):242–8.

30. Villeneuve E, Narn JL, Bell MJ, Deighton CM, Felson DT, Hazes JM, et al. A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. Postgrad Med J. 2013;89(1050):231–8.

31. van Omna M, Gorter S, Maiburg B, Waegenaar G, van Tubergen A. Education improves referral of patients suspected of having spondyloarthritis by general practitioners: a study with unannounced standardised patients in daily practice. RMD Open. 2015;1(1):e000152.

32. Gladman DD, Schentag CT, Tom BD, Chandran V, Brockbank J, Rosen C, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis. 2009;68(4):497–501.

33. Tom BD, Chandran V, Farewell VT, Rosen CF, Gladman DD. Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS). J Rheumatol. 2015;42(5):841–6.

34. Haberman R, Perez-Chada LM, Merola JF, Scher J, Ogdie A, Reddy SM. Bridging the gaps in the care of psoriasis and psoriatic arthritis: the role of combined clinics. Curr Rheumatol Rep. 2018;20(12):76.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions